Cibus Global LLC - Asset Resilience Ratio
Cibus Global LLC (CBUS) has an Asset Resilience Ratio of 5.81% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Cibus Global LLC for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2021)
This chart shows how Cibus Global LLC's Asset Resilience Ratio has changed over time. See CBUS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cibus Global LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CBUS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.04 Million | 5.81% |
| Total Liquid Assets | $3.04 Million | 5.81% |
Asset Resilience Insights
- Limited Liquidity: Cibus Global LLC maintains only 5.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cibus Global LLC Industry Peers by Asset Resilience Ratio
Compare Cibus Global LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Cibus Global LLC (2016–2021)
The table below shows the annual Asset Resilience Ratio data for Cibus Global LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $37.19 Million | -- |
| 2020-12-31 | 18.47% | $11.70 Million | $63.33 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $88.10 Million | -- |
| 2017-12-31 | 0.56% | $402.00K | $72.17 Million | -2.66pp |
| 2016-12-31 | 3.22% | $535.00K | $16.62 Million | -- |
About Cibus Global LLC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-th… Read more